CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma....
Phase 1, Phase 2
Nashville, Tennessee, United States and 31 other locations
of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas...
Phase 1
Nashville, Tennessee, United States and 11 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...
Phase 2
Nashville, Tennessee, United States and 71 other locations
primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma...
Phase 1
Nashville, Tennessee, United States and 4 other locations
patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment op...
Phase 1
Nashville, Tennessee, United States and 16 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Nashville, Tennessee, United States and 41 other locations
by the intravenous (IV) route to participants with solid tumors or lymphomas.The main goals of this study are to:* Find the recommended dose...
Phase 1, Phase 2
Nashville, Tennessee, United States and 8 other locations
in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus za...
Phase 3
Nashville, Tennessee, United States and 150 other locations
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib...
Phase 3
Nashville, Tennessee, United States and 194 other locations
dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as...
Phase 1
Nashville, Tennessee, United States and 12 other locations
Clinical trials
Research sites
Resources
Legal